Prev Arrow Stocks

Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Down 5.1% Today

Morpher AI identified a bearish signal. The stock price may continue to fall based on the momentum of the negative news.

What is Tandem Diabetes Care, Inc.?

Tandem Diabetes Care (TNDM) is a company specializing in diabetes management products, such as insulin pumps. The market sentiment for TNDM was bearish.

Why is Tandem Diabetes Care, Inc. going down?

TNDM stock is down 5.1% on Aug 11, 2025 14:25

  • TNDM stock saw a significant decline after its Q2 earnings announcement, despite surpassing revenue expectations and boosting gross margin. The drop was a result of missed earnings and reduced guidance, leading to a 20% decrease in share price.
  • Concerns about device recalls and malfunctions added to the stock's plunge, with a considerable number of adverse incidents and injuries reported. This raised apprehensions among investors regarding the quality and safety standards of the company's products.
  • Despite the bearish trend, some experts suggest that TNDM might be approaching a support level, as evidenced by a hammer chart formation. Moreover, the consensus among financial analysts in increasing earnings projections could hint at a buying opportunity for investors interested in the company's long-term potential.

TNDM Price Chart

TNDM Technical Analysis

TNDM News

Top 3 Health Care Stocks That Are Preparing To Pump This Month - Exact Sciences ( NASDAQ:EXAS ) , Outset Medical ( NASDAQ:OM )

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.

https://www.benzinga.com/trading-ideas/long-ideas/25/08/47027986/top-3-health-care-stocks-that-are-preparing-to-pump-this-month

0 News Article Image Top 3 Health Care Stocks That Are Preparing To Pump This Month - Exact Sciences  ( NASDAQ:EXAS ) , Outset Medical  ( NASDAQ:OM )

TNDM Stock Falls on Q2 Earnings Miss, Revenues Beat, Gross Margin Up

Tandem Diabetes posts record Q2 sales and higher margins, but earnings miss sends shares tumbling 20%.

https://www.zacks.com/stock/news/2696690/tndm-stock-falls-on-q2-earnings-miss-revenues-beat-gross-margin-up

1 Missing News Article Image TNDM Stock Falls on Q2 Earnings Miss, Revenues Beat, Gross Margin Up

Why Is Insulet Peer Tandem Diabetes Stock Trading Lower Today - Tandem Diabetes Care ( NASDAQ:TNDM )

Tandem posts a Q2 loss of $0.78 vs. $0.40 estimate; the stock plunges due to guidance cuts and device recalls. 700 adverse events and 59 injuries linked to malfunctioning insulin pumps trigger medical device correction. Get ahead of next week's CPI & PPI with Chris Capre's live trading strategy ...

https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/08/46974595/insulet-peer-tandem-diabetes-underwhelming-earnings-dull-outlook-drags-stock

2 News Article Image Why Is Insulet Peer Tandem Diabetes Stock Trading Lower Today - Tandem Diabetes Care  ( NASDAQ:TNDM )

Tandem Diabetes Care, Inc. ( TNDM ) Reports Q2 Loss, Beats Revenue Estimates

Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of -20.00% and +0.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2675162/tandem-diabetes-care-inc-tndm-reports-q2-loss-beats-revenue-estimates

3 Missing News Article Image Tandem Diabetes Care, Inc.  ( TNDM )  Reports Q2 Loss, Beats Revenue Estimates

Bears are Losing Control Over Tandem Diabetes Care ( TNDM ) , Here's Why It's a 'Buy' Now

Tandem Diabetes Care (TNDM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential ...

https://www.zacks.com/stock/news/2667754/bears-are-losing-control-over-tandem-diabetes-care-tndm-heres-why-its-a-buy-now

4 Missing News Article Image Bears are Losing Control Over Tandem Diabetes Care  ( TNDM ) , Here's Why It's a 'Buy' Now

Tandem Diabetes Care, Inc. Price History

07.07.2025 - TNDM Stock was down 20.7%

  • Tandem Diabetes Care (TNDM) reported a Q2 loss of $0.78, missing the estimated $0.40, leading to a significant drop in the stock price.
  • The stock also suffered due to guidance cuts and device recalls, with adverse events and injuries linked to malfunctioning insulin pumps triggering a correction.
  • Despite the bearish movement, some analysts are optimistic about TNDM, pointing to technical chart patterns like the formation of a hammer chart and positive revisions in earnings estimates as reasons to consider it a 'buy' opportunity.

07.07.2025 - TNDM Stock was down 28.7%

  • TNDM exceeded revenue expectations but reported a loss in Q2, potentially influencing the bearish trend.
  • A hammer chart formation and positive adjustments in earnings forecasts from financial analysts hint at a possible turnaround for TNDM, suggesting a chance for investment.
  • Investor wariness following the company's recent loss may be contributing to the stock's downward movement.
  • Mixed signals from the earnings report and technical chart pattern may be causing uncertainty among investors, leading to TNDM's current downward trajectory.

11.07.2025 - TNDM Stock was down 5.1%

  • TNDM stock saw a significant decline after its Q2 earnings announcement, despite surpassing revenue expectations and boosting gross margin. The drop was a result of missed earnings and reduced guidance, leading to a 20% decrease in share price.
  • Concerns about device recalls and malfunctions added to the stock's plunge, with a considerable number of adverse incidents and injuries reported. This raised apprehensions among investors regarding the quality and safety standards of the company's products.
  • Despite the bearish trend, some experts suggest that TNDM might be approaching a support level, as evidenced by a hammer chart formation. Moreover, the consensus among financial analysts in increasing earnings projections could hint at a buying opportunity for investors interested in the company's long-term potential.

09.06.2025 - TNDM Stock was down 5.1%

  • TNDM likely experienced a bearish movement due to overall market sentiment affecting investor confidence.
  • The downbeat sales reported by Aehr Test Systems may have contributed to a negative investor outlook on the sector, leading to a ripple effect on TNDM.
  • Investors may have reacted to the worse-than-expected sales results, causing a shift towards more cautious trading strategies and selling off positions in companies like TNDM.
  • The mixed stock movements in the pre-market session could have added to the uncertainty, prompting investors to take a more risk-averse approach and sell off shares in TNDM.

01.04.2025 - TNDM Stock was up 16.8%

  • Tandem Diabetes Care (TNDM) posted a loss in Q1 but outperformed revenue expectations, showcasing strong top-line growth.
  • Despite the earnings shortfall, the stock displayed a bullish trend, hinting at investor focus on the revenue beat and future growth possibilities.
  • The market appears bullish on TNDM's capability to benefit from the rising demand for diabetes management solutions, fueling the positive movement.
  • Investors seem to be optimistic about TNDM's long-term potential in the healthcare sector and are overlooking the short-term loss, contributing to the upbeat market sentiment.

19.02.2025 - TNDM Stock was up 5.4%

  • Tandem Diabetes (TNDM) stock witnessed a bullish movement after the commercial launch of Control-IQ+ technology in the United States.
  • The launch of Control-IQ+ technology, compatible with Tandem's insulin pump systems, has likely sparked enthusiasm among investors and consumers.
  • The successful introduction of this advanced technology showcases Tandem Diabetes' dedication to innovation and addressing the needs of the diabetes management market, potentially enhancing investor confidence in the company's growth prospects.
  • The positive market response indicates the potential for increased sales and market share for Tandem Diabetes as it expands its product line and strengthens its position in the healthcare technology sector.

02.04.2025 - TNDM Stock was up 5.0%

  • TNDM stock saw a bullish uptrend despite falling short on Q1 earnings, driven by robust sales growth domestically and internationally.
  • The company's improved gross margin suggests enhancing operational efficiency, reflecting positively on investors.
  • Exceeding revenue estimates while facing a loss indicates market optimism regarding TNDM's future performance and growth prospects.
  • Investors are focusing on revenue beat and sales growth, leading to the upbeat movement in TNDM stock, overshadowing the earnings miss.

30.04.2025 - TNDM Stock was down 5.2%

  • The recent earnings report for TNDM was positive, with the stock price increasing by 6.5% since the last report.
  • Despite the positive earnings, the market might have reacted bearishly due to profit-taking by investors who saw the recent gains as an opportunity to sell.
  • Investors may also be concerned about future growth prospects or external factors impacting the company's performance, leading to the bearish movement today.
  • Monitoring upcoming news and developments related to TNDM is important to better understand market sentiment and potential future movements.

31.06.2025 - TNDM Stock was down 5.0%

  • The bearish movement in TNDM stock today could be due to profit-taking by investors who were anticipating a positive earnings report.
  • Despite expectations of beating earnings estimates, market conditions or external factors might have influenced the stock's downward movement.
  • Investors may have reacted negatively to any unexpected news or developments within the company that were not captured in the earnings expectations.
  • It's possible that market sentiment shifted, leading to a sell-off in TNDM shares despite the positive outlook for earnings.

10.03.2025 - TNDM Stock was down 5.4%

  • TNDM stock experienced strong bearish movement, despite being a significant mover in the previous session.
  • Recent trends in earnings estimate revisions could have influenced the stock's decline.
  • Market skepticism regarding TNDM's capacity to maintain its recent strength resulted in today's bearish movement.

06.07.2025 - TNDM Stock was down 5.0%

  • Despite recent losses, TNDM seems to have found support indicated by a hammer chart pattern, suggesting a potential reversal in the stock's movement.
  • Wall Street analysts are showing strong agreement in revising earnings estimates higher for TNDM, indicating confidence in the stock's potential.
  • The bullish sentiment from analysts combined with the technical chart pattern could be signaling a buying opportunity for investors looking to capitalize on the potential turnaround in TNDM's stock price.

22.06.2025 - TNDM Stock was up 5.2%

  • TNDM observed a noteworthy upward movement today, potentially influenced by investors interpreting the recent selling pressure as a buying opportunity.
  • The technical analysis indicating TNDM being in oversold territory might have attracted value investors on the lookout for a possible stock price recovery.
  • The consensus among financial analysts raising earnings estimates for TNDM might have also played a role in fostering positive sentiment, hinting at a potential uptick in the stock's performance.
  • In summary, the amalgamation of technical indicators and analyst outlook may have been key drivers behind the positive movement in TNDM today, as investors aimed to benefit from what they viewed as an undervalued stock.
i
Disclaimer
Morpher is not liable for the content of the AI investment insights. Like most GPT-powered tools, these summaries may contain AI hallucinations and inaccurate information. Morpher is not presenting you with any investment advice. All investments involve risk, and the past performance of a security, industry, sector, market, or financial product does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. Such decisions should be based solely on an evaluation of their financial circumstances, investment objectives, risk tolerance, and liquidity needs. These summaries do not constitute investment advice.